 | Up a level |
Journal Article
Janne, P. A., van den Heuvel, M., Barlesi, F., Cobo, M., Mazieres, J., Crino, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., Poltoratskiy, A., Mariani, G., Ghiorghiu, D., Kilgour, E., Smith, P., Kohlmann, A., Carlile, D., Lawrence, D., Bowen, K. and Vansteenkiste, J. F. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Souquet, P-J., Kim, S-W., Solomon, B., Vansteenkiste, J. F., Carbini, M., Jary, A., Glaser, S., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study. Ann. Oncol., 32. S. S1033 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041